HUMAW — Humacyte, Inc.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1818382 ·
Last close
—
Market Cap
—
52W High
—
52W Low
—
ADV30
—
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 495,000 | -1,543,000 | -28,935,000 | -17,619,000 | 110,557,000 | 48,539,000 | 98,933,000 |
| Dec 2025 | 467,000 | -8,615,000 | -30,836,000 | -24,804,000 | 116,366,000 | 50,497,000 | 113,257,000 |
| Sep 2025 | 753,000 | 493,000 | -24,390,000 | -17,510,000 | 91,509,000 | 19,488,000 | 96,260,000 |
| Jun 2025 | 301,000 | 88,000 | -29,727,000 | -37,658,000 | 138,795,000 | 38,032,000 | 134,743,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-101,545,000
Investing CF
$-831,000
Financing CF
$38,068,000
CapEx
$-831,000
Dividends Paid
$0
Buybacks
—
EPS Diluted TTM
—
As of
2026-08-16
Balance + Analyst (yfinance extras)
Retained Earnings
$-744,467,000
Inventory
$9,920,000
Receivables
$434,000
ST Investments
—
EBIT TTM
$-87,070,000
Pretax Income TTM
$-97,591,000
Interest Exp TTM
$10,521,000
Analysts
—
Yahoo Snapshot (yfinance, live)
Total Revenue
$2,121,000
EBITDA
$-103,228,000
Free Cash Flow
$-58,393,248
Enterprise Value
—
Total Cash
$79,903,000
Total Debt
$66,880,000
Shares Out
—
Trailing EPS
$-3.16
Book Value
$0.11
ROE
-547.9%
ROA
-49.9%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 2,038,000 | -108,137,000 | -40,833,000 | 116,366,000 | 113,257,000 | — | -105,042,000 |
| Dec 2024 | 0 | -114,398,000 | -148,701,000 | 137,872,000 | 190,541,000 | — | -98,122,000 |
| Dec 2023 | 0 | -100,047,000 | -110,776,000 | 128,223,000 | 114,677,000 | — | -73,305,000 |
| Dec 2022 | 0 | -84,578,000 | -11,965,000 | 204,302,000 | 87,374,000 | — | -71,129,000 |
TTM Snapshot
Revenues TTM
$2,738,000
NetIncome TTM
$-130,394,000
OpCashFlow TTM
$0
Assets (Latest)
$137,872,000
Forward EPS
—
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| AMGN | AMGEN INC | $239.95B | $443.84 | — |
| GILD | GILEAD SCIENCES, INC. | $181.95B | $146.74 | — |
| ARGX | ARGENX SE | $63.26B | $1011.11 | — |
| MRNA | Moderna, Inc. | $55.45B | $138.89 | — |
| RVMD | Revolution Medicines, Inc. | $45.35B | $211.58 | — |
News headlines (Yahoo Finance, 1h cache)
Humacyte, Inc. (HUMA) Suffers a Larger Drop Than the General Market: Key Insights
2026-07-20 22:15 · Yahoo
Humacyte, Inc. (HUMA) Beats Stock Market Upswing: What Investors Need to Know
2026-07-14 22:15 · Yahoo
Humacyte Confirms Plans for ATEV Supplemental BLA Filing for Dialysis Access Following FDA Discussions
2026-08-24 12:00 · Yahoo
Humacyte (HUMA) Q2 2026 Earnings Call Transcript
2026-08-19 14:13 · Yahoo
Humacyte Announces Lancet Digital Health Publication of V007 Phase 3 Hemodialysis Access Trial Results
2026-08-19 12:00 · Yahoo
Board-Certified Vascular and Endovascular Surgeon Performs First Commercial Symvess® Implantation; Cites Bioengineered Blood Vessel as “Revolutionary Advancement”
2026-08-18 12:00 · Yahoo
Humacyte (HUMA) Faces A Fresh Test As Its $4 Fair Value Narrative Holds
2026-08-13 21:09 · Yahoo
Humacyte (HUMA) Stock Looks Stretched On Book Value Yet Reasonable After A 93% Fall
2026-08-13 12:09 · Yahoo
Humacyte (HUMA) Reports Stronger Phase 3 Dialysis Results In Women
2026-08-13 11:11 · Yahoo
Humacyte Inc (HUMA) (Q2 2026) Earnings Call Highlights: Strong Trial Results and Strategic ...
2026-08-12 23:04 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.